0RKL.LSE

Xvivo Perfusion AB

0RKL.LSE, UK

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

https://www.xvivogroup.com

Stock Price

SEK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

7.77

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

2.64

Low 1

High 3

Return on Equity (ROE)

-

Very Low

0.21 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

0.18 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.14

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Xvivo Perfusion AB

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-5.9

Latest Release

Date

2025-09-30

EPS Actual

0.1375

EPS Estimate

2.06

EPS Difference

-1.9225

Surprise Percent

-93.3252%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4.5)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

SEK 0

Cost Of Revenue

SEK 0

Gross Profit

SEK 0

Operating Expenses

SEK 0

Operating Income

SEK 0

Interest Expense

SEK 0

Pretax Income

SEK 0

Net Income

SEK 0

Income Tax Expense

SEK 0

EBITDA

SEK 0

Total Other Income Expense Net

SEK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

SEK 0

Short Term Investments

SEK 0

Receivables

SEK 0

Inventories

SEK 0

Total Current Assets

SEK 0

Property Plant Equipment

SEK 0

Total Assets

SEK 0

Payables

SEK 0

Short Term Debt

SEK 0

Long Term Debt

SEK 0

Total Liabilities

SEK 0

Equity

SEK 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

SEK 0

Depreciation

SEK 0

Change In Working Capital

SEK 0

Cash From Operations

SEK 0

Capital Expenditures

SEK 0

Cash From Investing

SEK 0

Cash From Financing

SEK 0

Net Change In Cash

SEK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.